1. High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.
- Author
-
Ronald C Hendrickson, Anita Y H Lee, Qinghua Song, Andy Liaw, Matt Wiener, Cloud P Paweletz, Jeffrey L Seeburger, Jenny Li, Fanyu Meng, Ekaterina G Deyanova, Matthew T Mazur, Robert E Settlage, Xuemei Zhao, Katie Southwick, Yi Du, Dan Holder, Jeffrey R Sachs, Omar F Laterza, Aimee Dallob, Derek L Chappell, Karen Snyder, Vijay Modur, Elizabeth King, Catharine Joachim, Andrey Y Bondarenko, Mark Shearman, Keith A Soper, A David Smith, William Z Potter, Ken S Koblan, Alan B Sachs, and Nathan A Yates
- Subjects
Medicine ,Science - Abstract
Disease modifying treatments for Alzheimer's disease (AD) constitute a major goal in medicine. Current trends suggest that biomarkers reflective of AD neuropathology and modifiable by treatment would provide supportive evidence for disease modification. Nevertheless, a lack of quantitative tools to assess disease modifying treatment effects remains a major hurdle. Cerebrospinal fluid (CSF) biochemical markers such as total tau, p-tau and Ab42 are well established markers of AD; however, global quantitative biochemical changes in CSF in AD disease progression remain largely uncharacterized. Here we applied a high resolution open discovery platform, dMS, to profile a cross-sectional cohort of lumbar CSF from post-mortem diagnosed AD patients versus those from non-AD/non-demented (control) patients. Multiple markers were identified to be statistically significant in the cohort tested. We selected two markers SME-1 (p
- Published
- 2015
- Full Text
- View/download PDF